News Focus
News Focus
Replies to #94190 on Biotech Values
icon url

DewDiligence

04/14/10 9:57 PM

#94192 RE: apljack #94190

…the [Gammagard] decline in ADAS scores for treatment patients are grossly in line with Aricept studies if memory serves.

That’s surprising—I need to check the Aricept label to see if your memory serves. (If not, you might be more interested in Aricept than you thought :- ))
icon url

masterlongevity

04/14/10 11:27 PM

#94194 RE: apljack #94190

" but the decline in ADAS scores for treatment patients are grossly in line with Aricept studies if memory serves."

I would argue that the change in ADAS score are meaningless (for this type of medication (of course, am sure FDA disagrees)). the real goal is to change the course of the disease and then to treat earlier so that patients have a chacne not to become this demented.
icon url

genisi

04/15/10 3:19 AM

#94201 RE: apljack #94190

BAX-Gammagard:

How frequent are the infusions?

If it is once every two-weeks infusion as in the 1st phase III trial, it's a hassle alright.

Aricept trials showed a 1.3 point ADAS-cog improvement vs. placebo and a 3.1 point improvement vs. baseline for the 10mg QD dose at six months.